In the wake of China's economic
growth and enhanced disease prevention awareness, Chinese human vaccine market
has been expanding. In 2012, Chinese human vaccine market valued RMB10.5
billion with the lot release quantity of roughly 773 million person-portions.
Restricted by China's national conditions and policies, EPI vaccines still
prevail in China and Chinese EPI vaccine market is almost monopolized by
state-run enterprises represented by CNBG Tiantan Biological, Biological
Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and
Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming.
In 2012, state-owned enterprises seized 81.5% of the vaccine lot release
quantity in Chinese EPI vaccine market.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/china-human-vaccine-industry-report-2012-2015
However, along with the gradual
relaxed access to the vaccine market, private companies have sprung up in the
Extra EPI vaccine market and acquired more market share. Meanwhile, foreign
counterparts occupy considerable market share by virtue of their technological
and product advantages. In 2012, private and foreign-funded enterprises
occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine
market respectively. As for human rabies vaccine and varicella vaccine markets,
they mastered more than 85% of each.
In recent years, China has made some
achievements in overseas vaccine markets. In 2011-2012, China’s annual human
vaccine export volume remained over 9,000 tons (9,840 tons in 2010 was subject
to the accidental H1N1 flu event), far more than 8,110 tons in 2009. Moreover,
many domestic vaccine companies are still planning overseas markets
aggressively.
By the end of 2012, the first batch
of Hib vaccine products of Walvax Biotechnology were approved by China Customs
and exported to Manila, Philippines for official marketing. Walvax
Biotechnology is promoting the product registration in Russia, India, Thailand
and other countries. In November 2012, Hualan Biological Engineering mailed
three consecutive batches of samples for influenza virus split vaccine to WHO
for testing. The company is expected to receive WHO’s spot verification
certification in 2013. On March 7, 2013, Tiantan Biological obtained the
production approval for polio attenuated live vaccine (liquid OPV). In
accordance with the cooperation agreement with Bill & Melinda Gates
Foundation in 2011, Tiantan Biological will supply OPV to United Nations
International Children’s Emergency Fund (UNICEF) formally.
In addition, it is worth mentioning
that the industrialization of the world's first recombinant hepatitis E vaccine
(Escherichia coli) developed by Xiamen University and YangShengTang INNOVAX
jointly was realized on October 27, 2012. As of the end of 2012, the lot
release quantity of the product hit 90,000 person-portions.
China Human Vaccine Industry Report,
2012-2015 mainly contains the following aspects:
- Operating environment, status quo, market supply and demand, competition pattern and development prospects of human vaccine in China;
- Market supply and demand, competition patterns, market prices and development trends of 10 kinds of products including hepatitis B vaccine, influenza vaccine, Hib vaccine, human rabies vaccine and pneumococcal vaccine in China;
- Import & export volume and value as well as import sources & export destinations of human vaccine in China;
- 20120114.gif?Operation, revenue structure, vaccine business and development trends of 11 Chinese vaccine enterprises including Tiantan Biological, Hualan Biological Engineering, Zhifei Biological, Walvax Biotechnology and Sinovac Biotech.
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll
Free: 866-997-4948
No comments:
Post a Comment